New hope for kids with tough leukemia: drug combo trial shows promise
NCT ID NCT04915612
First seen Mar 03, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This early-stage trial tested a combination of two chemotherapy drugs (CPX-351) and a targeted antibody (GO) in children whose acute myeloid leukemia (AML) had returned or didn't respond to standard treatment. The goal was to find the safest dose and see if the combo could help control the disease. Only one child took part, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.